[Prosthesis designs for the partially edentulous jaw].

Le résumé fourni par la source

179 Objectives In breast cancer, FDG-PET has been shown to be useful in restaging and evaluating response to therapy. In many cancers, FDG-PET is known to be correlated with survival. We investigated the prognostic value of FDG-PET in terms of survival in the setting of recurrent ER+ breast cancer. Methods Sixty patients suspected of having a recurrence of a previously treated ER+ breast cancer were prospectively enrolled in the study from March 2002 to April 2008. All patients had a FDG-PET at the time of suspected recurrence and approximately two months after initiating treatment. Qualitative interpretation and a SUV of 2.5 were used as the cut-off value to dichotomize positive FDG-PET scans from negative studies. Usual clinical follow-up then ensued. Results Twenty-five percent (15/60) of the patients died during follow-up. The median clinical follow-up was 40 months. Patients with a positive FDG-PET either at the time of suspected recurrence or two months after initiating treatment had a significantly shorter survival (p=0.01). No patient with a proven recurrence and a negative FDG-PET (either at the time of suspected recurrence or approximately two months after initiating treatment) died during follow-up. Conclusions FDG-PET is a strong predictor of survival in recurrent ER+ breast cancer, both at the time of suspected recurrence and two months after initiating treatment. This finding could help determine the appropriate level of treatment aggressiveness in this setting. Research Support Canadian Breast Cancer Research Alliance

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.